Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedWatch forms continued

This article was originally published in The Tan Sheet

Executive Summary

FDA asks the Office of Management and Budget for a three-year extension of the MedWatch form for mandatory reports from firms marketing medical devices, Rx and OTC drugs and dietary supplements. In a Sept. 24 Federal Register notice, the agency says the instructions on the MedWatch form will be changed to reflect that AERs for OTCs and supplements now are mandatory (1"The Tan Sheet" Dec. 18, 2006, p. 4). No changes are proposed for "any content or formatting," the notice says. Dietary supplement industry stakeholders told FDA that the MedWatch form was developed for reporting pharmaceutical adverse events, but including all information relevant to some supplement-related events customers report will be difficult with the current form. The deadline for comments on the notice is Oct. 24

You may also be interested in...

Adverse Event Collection Expected To Be In Force By Christmas 2007

Firms that make, pack or distribute dietary supplements and over-the-counter drugs approved under monographs will likely have to be in compliance with a new adverse event reporting law by late December 2007

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts